CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 324 enrolled
Drug / intervention
TAXUS® Liberté™ +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01171820
NCT01171820Phase 4Completed
CompareCT.gov

SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions

Abbott Medical Devices·interventional·Posted Jul 29, 2010·Updated Jun 27, 2016

In Brief

A Phase 4 clinical trial evaluating TAXUS® Liberté™ and XIENCE V® EECSS for Coronary Disease and 2 related conditions. Completed, enrolled 324 participants across 28 sites in 11 countries.

Detailed Summary

The purpose of this Clinical Evaluation is a continuation in the assessment of the performance of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the treatment of patients with de novo coronary artery lesions in patients (Diabetic sub-study).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Disease, Coronary Artery Disease, Coronary Restenosis
CountriesAustria, France, Germany, Israel, Italy, Malaysia, Netherlands, Poland, Spain, Thailand, United Kingdom
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 29, 2010
Enrollment StartNov 1, 2006
Primary CompletionJul 1, 2009
Study CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 15.9 years ago

Interventions

TAXUS® Liberté™device

Drug eluting stent implantation stent in the treatment of coronary artery disease in participants with Diabetes

XIENCE V® EECSSdevice

Drug eluting stent implantation stent in the treatment of coronary artery disease in participants with Diabetes